Table 2.
Association between OATP1B3 expression/immunostaining and clinicopathological parameters in 278 colon cancers
|
OATP1B3 expression (Total n = 278) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Variable | subgroup | Negative |
Positive |
p-value | ||||
| n | (n = 123) | Moderate (n = 90) | High (n = 50) | |||||
| Age at surgery (y) | 66.1 ± 15.8 | 68.7 ± 13.1 | 70.0 ± 12.4 | 0.146 | ||||
| Sex | 0.312 | |||||||
| Male (n = 135) | 135 | 54 | 40.0% | 49 | 36.3% | 32 | 23.7% | |
| Female (n = 143) | 143 | 69 | 48.3% | 41 | 28.7% | 33 | 23.1% | |
| Differentiation | 0.004 | |||||||
| High-grade (n = 168) | 168 | 80 | 47.6% | 60 | 35.7% | 28 | 16.7% | |
| Low-grade (n = 96) | 96 | 42 | 43.8% | 28 | 29.2% | 36 | 37.5% | |
| unknown (n = 4) | 4 | 1 | 2 | 1 | ||||
| Tumor stage | 0.003 | |||||||
| 1 (n = 17) | 17 | 6 | 35.3% | 7 | 41.2% | 4 | 23.5% | |
| 2 (n = 163) | 163 | 67 | 41.1% | 45 | 27.6% | 51 | 31.3% | |
| 3 (n = 66) | 66 | 38 | 57.6% | 24 | 36.4% | 4 | 6.1% | |
| 4 (n = 32) | 32 | 12 | 37.5% | 14 | 43.8% | 6 | 18.8% | |
| Lymphovascular invasion | 0.727 | |||||||
| No | 222 | 99 | 44.6% | 69 | 31.1% | 54 | 24.3% | |
| Yes | 52 | 21 | 40.4% | 20 | 38.5% | 11 | 21.2% | |
| unknown | 4 | 3 | 1 | 0 | ||||
| Recurrence (Stages I, II, and III only)* | 0.037 | |||||||
| No | 173 | 70 | 40.5% | 55 | 31.8% | 48 | 27.7% | |
| Yes | 72 | 41 | 56.9% | 20 | 27.8% | 11 | 15.3% | |
| unknown or stage IV | 33 | 12 | 15 | 6 | ||||
| Overall survival (All stages, n = 278) | 0.001 | |||||||
| ≥5 years | 112 | 44 | 39.3% | 29 | 25.9% | 39 | 34.8% | |
| <5 years | 166 | 79 | 47.6% | 61 | 36.7% | 26 | 15.7% | |
Note:
*
Stage IV patients were not included in the tumor recurrence analysis.